Press & News

People are different and so is their cancer, patients should be treated individually.

Meet us at LSX Nordic Congress

July 26, 2018


2cureX participates in Life Science Executives, Leadership and Investment Congress in Stockholm, 29th to 30th August 2018, where CEO Ole Thastrup talks about 2cureX and our product IndiTreat®, which helps clinicians choose the most appropriate treatment for cancer patients.

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO;        


Phone: +45 22 11 53 99;               


About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).